1. Home
  2. USA vs NRIX Comparison

USA vs NRIX Comparison

Compare USA & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

USA

Liberty All-Star Equity Fund

HOLD

Current Price

$6.37

Market Cap

1.9B

Sector

Finance

ML Signal

HOLD

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$17.43

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
USA
NRIX
Founded
1986
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.7B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
USA
NRIX
Price
$6.37
$17.43
Analyst Decision
Strong Buy
Analyst Count
0
13
Target Price
N/A
$27.46
AVG Volume (30 Days)
880.5K
1.8M
Earning Date
01-01-0001
01-27-2026
Dividend Yield
9.66%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$83,687,000.00
Revenue This Year
N/A
$59.40
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
48.32
52 Week Low
$5.62
$8.18
52 Week High
$7.09
$22.50

Technical Indicators

Market Signals
Indicator
USA
NRIX
Relative Strength Index (RSI) 62.14 45.83
Support Level $6.22 $18.78
Resistance Level $6.34 $19.54
Average True Range (ATR) 0.07 0.86
MACD 0.01 -0.41
Stochastic Oscillator 98.08 10.77

Price Performance

Historical Comparison
USA
NRIX

About USA Liberty All-Star Equity Fund

Liberty All Star Equity Fund is a multi-managed fund. Its objective is to provide a high level of current income and long-term capital appreciation through investing principally in a diversified portfolio of equity securities. The fund invests in various sectors, including financials, information technology, healthcare, consumer discretionary, consumer staples, industrials, energy, materials, real estate, utilities, telecommunication, and other services.

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Share on Social Networks: